A health ministry panel on August 22 discussed how drugs’ cost effectiveness should be assessed with the ICER (incremental cost-effectiveness ratio) under an envisaged full-scale CEA scheme when they carry multiple indications that yield multiple ICER values. The handling…
To read the full story
Related Article
- Chuikyo to Allow “Ranged” ICER Values in Cost-Effective Assessment
August 23, 2018
- Chuikyo Members Call for More Info Disclosure for CEA Scheme
August 23, 2018
REGULATORY
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
- MHLW to Reconvene HSC Regulation Panel for First Time in a Year
July 17, 2026
- MHLW Allows Exceptional Concerta Pharmacy Transfers
July 17, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





